Let's dive into the world of healthcare stocks and explore some intriguing investment opportunities for 2026. Today, we'll be focusing on two pharmaceutical giants, Biogen and Novo Nordisk, and the unique paths they've taken to success.
The Neurology Specialist vs. The Metabolic Health Leader
Biogen and Novo Nordisk represent contrasting approaches within the healthcare sector. Biogen, a neurology specialist, has built a strong portfolio of drugs to treat various neurological conditions, from multiple sclerosis to Alzheimer's disease. On the other hand, Novo Nordisk has emerged as a leader in the metabolic health revolution, particularly in diabetes and obesity treatments.
Three Reasons to Consider Each Stock
Biogen: A Turnaround Story
Biogen's focus on neurological conditions has led to a diverse range of treatments, including Leqembi for early Alzheimer's and Spinraza for spinal muscular atrophy. Despite a recent setback with the FDA's extended review of Leqembi's subcutaneous formulation, the company remains profitable. In fact, Q1 2026 saw a 2% increase in revenue and a 31% jump in earnings per share (EPS). This is largely due to the impressive 74% rise in Leqembi sales. Biogen's acquisitions, such as Reata Pharmaceuticals and Apellis Pharmaceuticals, have further strengthened its pipeline, adding promising rare-disease treatments and diversifying its portfolio.
What makes this particularly fascinating is Biogen's ability to navigate the challenges of generic competition for its older blockbuster drugs. Through strategic acquisitions, the company has broadened its horizons and positioned itself for long-term growth.
Novo Nordisk: A Growth Machine
Novo Nordisk, a Danish powerhouse, has dominated the markets for diabetes and obesity treatments with its GLP-1 agonists, Ozempic, and Wegovy. Despite strong competition from Eli Lilly's Zepbound, Novo Nordisk continues to report record revenue. The company's strategic move to gain FDA approval for the injectable form of Wegovy in 2021, well ahead of Lilly's Zepbound, showcases its ability to stay ahead of the curve. This year, Novo Nordisk further expanded its reach with the approval of Wegovy in pill form, followed by Lilly's Foundayo.
In Q1 2026, Novo Nordisk reported impressive revenue of $15.3 billion, a 24% increase year-over-year, with operating profit up 54% to $9.4 billion. The company's success has allowed it to broaden its portfolio, acquiring Akero Therapeutics for $4.7 billion, which brought in a late-stage candidate, efruxifermin, showing promise in reversing liver scarring. Novo Nordisk's GLP-1 therapies are also receiving label expansions, enhancing their clinical versatility and strengthening the company's competitive position.
A Deeper Analysis
Both Biogen and Novo Nordisk offer unique investment opportunities, but which one takes the lead? Biogen, with its turnaround story and promising portfolio, appears well-priced and is likely in the early stages of a growth trajectory. However, Novo Nordisk's stronger growth profile and lower earnings multiple make it an attractive long-term choice. Its ability to fund its own development and acquisitions with GLP-1 agonist sales, coupled with an above-average dividend, positions it as a solid investment.
In my opinion, Novo Nordisk edges out Biogen as the better buy right now. But remember, investing is about more than just numbers; it's about understanding the story behind the stock and its potential for future growth. So, keep an eye on these healthcare giants and their innovative approaches to healthcare solutions.
